Applied Pharmaceutical Analysis 2022 

 In-Person Event

In case you are not sure about travel, remote attendance option will also be made available, and you can switch between in-person and

remote options anytime.
September 19-21, Embassy Suites by Hilton Boston Waltham






Regulated Bioanalysis Workshop - Monday, September 19, 2022

Discovery Bioanalysis and New Technologies Workshop - Tuesday, September 20, 2022

Mechanistic ADME Workshop - Wednesday, September 21, 2022

Hypha banner


FR116 AAP leaderboard dig bnr 728x90 r1

Pat Walters


 Pat Walters, PhD

Chief Data Officer @ Relay Therapeutics

Challenges and Opportunities for AI in ADME Modeling

  Parag Mallick


 Parag Mallick, PhD

Founder & Chief Scientist at Nautilus Biotechnology, Associate Professor @ Stanford University

The Role of Single-Cell and Single-Molecule Proteomics in Therapeutic Development

Malaz Abutarif


 Malaz Abutarif, PhD

Vice President of Quantitative Clinical Pharmacology @ Daiichi Sankyo

Clinical Pharmacology of ADCs: Critical Bioanalytical Role

steven j swanson APA2022


 Steven J Swanson, PhD, FAAPS

Senior Principal Scientist, Bioanalytical Sciences @ Genentech, Inc.

Immunogenicity Prediction - How Does This Fit in Drug Development

 Brian Booth

Brian Booth, PhD

Director DCP I, OCP, CDER, U.S. Food and Drug Administration

State of the FDA - Overview of Recent Guidances 

 Salaheldin Hamed

Salaheldin Hamed, PhD

Division of Cancer Pharmacology, OCP, CDER, U.S Food and Drug Adminstration

State of the FDA - Antibody Drug Conjugates

Amanda Hays 

  Amanda Hays, PhD

Scientific Officer @ BioAgilytix

Recommendations for Development and Validation of qPCR Assays for Regulated Bioanalysis



Jeffrey Kurz 

 Jeffrey Kurz, PhD

Associate Director @ Alnylam Pharmaceuticals

Intrathecal Delivery of siRna-Conjugates to the CNS: Challenges of ADME Characterization

 Stephen Fowler APA2022

  Stephen Fowler, PhD

Clinical Pharmacologist @ F. Hoffmann La-Roche Ltd

MPS for ADME Applications: Moving from Aspiration to Exploration

 Andy Pike

Andy Pike, PhD

Senior DMPK Lead @ AstraZeneca 

Optimising Proteolysis Targeting Chimeras (PROTAC's) for Oral Drug Delivery: A drug metabolism and pharmacokinetics perspective

Heather Myler APA2019 

  Heather Myler, PhD

Executive Director Scientific Affairs, Analytical Sciences Division @ PPD

Supply Chain Impact on Drug Development: A Pandemic-driven Global Perspective

 Christine Callahan APA2022

Christine Callahan, MS

Vice President Supply Chain, Life Sciences Solutions @ Thermo Fisher Scientific

Enhancement of Capacity and Supply Chain Capabilities - Title TBA

 Pallavi Lonkar APA2022

  Pallavi Lonkar, PhD

Senior Director, Head of Bioanalytical, DMPK and Biomarkers @ PepGen

 The Promise of Peptide-Oligonucleotide Conjugates for Neuromuscular Diseases


Shelia Breidinger, PhD

Director, Regulated Bioanalytical Outsourcing, Merck & Co, Inc.

Preclinical Bioanalytical Challenges in Supporting the COVID-19 Oral Antiviral, Molnupiravir, during a Pandemic


Yueting Wang

Yue-Ting Wang, PhD

Principal Reserarch Scientist, DMPK-BA @ AbbVie

To Infinity and Beyond Rule of Five Compounds: Challenges & Considerations for Discovery Stage Bioanalytical Support


Weixun Wang APA2022 


Weixun Wang, PhD

Group Leader Discovery Bioanalysis, Merck & Co, Inc.

Development of a Target Engagement (TE) Assay for the Oral Peptide PCSK9-LDLr Inhibitor Program

Jacques Saarbach

Jacques Saarbach, PhD

Post-doctoral Fellow, Crews Lab, MCDB, Yale University

Expanding the Protein Degradation Toolbox

Nanda B APA2022   

Nanda Balasubramanian, PhD

Senior Principal Scientist, Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb

Bioanalytical Strategies and Challenges for CAR-T Support

Michael Swanson 

Michael Swanson, PhD

Associate Scientific Director @ The Janssen Pharmaceutical Compaies of Johnson & Johnson

Bioanalytical Considerations for Assessing Immunogenicity of Cellular Therapy Products

Tomo Kiyota 

Tomomi Kiyota, PhD

Principal Scientist @ Genentech

Renal Proximal Tubule-on-a-Chip: Performance, Utility, and Benefits for Drug Development

Jason DelCarpini

Jason DelCarpini, PhD

Associate Director, Quantitative Bioanalytics @ Moderna

Practical Considerations for Neutralizing Antibody Assay Development

Michele Gunsior 


Michele Gunsior, PhD

Senior Director @ Astria Therapeutics

Recommendations for Harmonization of Anti-Drug Antibody Sample Testing and Reporting

Aaron Cooper 

  Aaron Cooper, PhD

Senior Director of Synthetic Biology @ Arsenal Bio

 Programming T Cell Therapies for Solid Tumors is Enabled by Precise Delivery of Large and Modular Gene Circuits With Multiple Therapeutic Functions

Haihong Shi 

Haihong Shi, PhD

Director @ Pfizer

Application of Micro-Sampling Device, Taso M20 in Pfizer's COVID-19 Therapeutics Drug PAXLOVID Development

Kenneth Swart 


 Kenneth Swart, PhD

SVP Bioanalytical and Biotherapeutic Sciences, Inotiv

Bioanalytical, Biotherapeutic, and Biomarker Analysis in Drug Development - Challenges and Solutions

Hisao Shimizu 

 Hisao Shimizu, PhD

Principal Scientist DMPK @ Takeda Pharmaceutical Company

Bioanalytical Approach for Diverse Oligonucleotides Therapeutics Using Multiple BA Platforms

Gregory Walker 

Gregory Walker, PhD

Associate Research Fellow @ Pfizer

The Crucial Role of NMR in Understanding the Human Disposition of PAXLOVID 

david stresser 


David Stresser, PhD

Senior Principal Scientist @ AbbVie

IQ Microphysiological Systems Affiliate: Accelerating the development and adoption of MPS models in industry

 Douglas Sparcklin

Douglas Spracklin, PhD

Director, Biotransformation & Environmental Sciences @ Pfizer

The AMS-enabled Human Absorption, Distribution, Metabolism & Excretion (hADME) Study: A Technological and Strategic Paradigm Shift

Laixin Wang 

 Laixin Wang, PhD

Co-Founder & Senior VP @ Chongqing Denali Medpharma & Helens Clinical Research Center

Hyphenated Liquid Chromatography Techniques and qPCR: Overcoming the Bioanalytical Challenges of Oligonucleotide Therapeutics and mRNA Vaccines


Donglu Zhang, PhD

Staff Scientist @ Genentech

The Importance of Tracking "Missing" Metabolites - How and Why?"


 Yongjun Xue, PhD

Scientific Director, Nonclinical Disposition and Bioanalysis @ Bristol-Myers Squibb

Use of 1β-Hydroxydeoxycholic Acid as a Potential Biomarker for Assessment of CYP3A DDI Activity

APA 2022 Sessions

Regulated Bioanalysis Workshop

Session I: The State of the FDA - Guidance, Approval, and Beyond

Session II: Roadmap to the Approval of COVID-19 Treatments and Testing

Session III: Immunogenicity and Bioanalytical Considerations

Session IV: Emerging Technologies for New Modalities & Biomarkers


Discovery Bioanalysis and New Technologies Workshop

Session I: Advancements in AAV, mRNA, and Lipid Nanoparticle Technology for Viral and Gene Therapies

Session II: Bioanalysis of Oligonucleotide Therapeutics

Session III: Beyond the Rule of Five: Considerations in Bioanalysis and Data Analysis


Mechanistic ADME Workshop

Workshop Theme: Unmasking Unmet Need in the ADMET Space

Session I: Microphysiological Systems: Recent Advances in 3D Cell Culture Models & Beyond to Address Unmet Needs in ADMET

Session II: On the Battlefield with Analytical Challenges

Session III: Mechanistic ADME of Novel Modalities


 Join our Linkedin Group:


Regulated Bioanalysis


Mechanistic ADME


Click here to register for the APA 2022 conference.

APA 2022 will take place September 19-21, 2022

Embassy Suites by Hilton Boston Waltham


The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3


Sign Up Today!

Privacy Policy